Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 872.33M P/E - EPS this Y -32.60% Ern Qtrly Grth -
Income -137.07M Forward P/E -5.61 EPS next Y 2.20% 50D Avg Chg 45.00%
Sales 137k PEG -0.01 EPS past 5Y - 200D Avg Chg 104.00%
Dividend N/A Price/Book 6.87 EPS next 5Y 294.10% 52W High Chg -6.00%
Recommedations 1.70 Quick Ratio 9.94 Shares Outstanding 28.02M 52W Low Chg 254.00%
Insider Own 32.23% ROA -32.82% Shares Float 19.25M Beta 1.28
Inst Own 47.92% ROE -73.59% Shares Shorted/Prior 2.18M/2.36M Price 31.13
Gross Margin 91.97% Profit Margin - Avg. Volume 295,216 Target Price 48.73
Oper. Margin -96,994.17% Earnings Date Mar 8 Volume 71,521 Change -1.68%
About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc. News
01/27/23 BTAI: Multiple Catalysts Ahead in 2023
01/11/23 BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
12/27/22 A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy
12/22/22 BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
12/19/22 BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
12/15/22 Why BioXCel Therapeutics Stock Jumped This Week
12/06/22 2 Beaten-Down Stocks to Watch Closely Next Year
12/02/22 Why BioXcel Therapeutics Stock Triumphed This Week
12/01/22 BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
07:00 AM BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
11/20/22 Is This Soaring Growth Stock a Buy?
11/14/22 BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
11/14/22 BTAI: Positive Early Metrics for IGALMI™ Launch…
11/10/22 BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
10/27/22 BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
10/05/22 BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
09/19/22 2 Growth Stocks That Could Double in the Next Year
09/07/22 BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
08/12/22 BTAI: SERENITY III Trial to Initiate in 2H22…
08/09/22 BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
BTAI Chatroom

User Image stockilluminati Posted - 9 hours ago

$BTAI https://www.stockilluminati.com/btai/news.php - BioXcel Therapeutics: Boldly Entering The Danger Zone With Launch Of IGALMI

User Image sgu1114 Posted - 13 hours ago

$BTAI https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_01272023_BTAI_Bautz.pdf

User Image ChartMill Posted - 1 day ago

$BTAI: The long and short term trends are both positive. This is looking good! https://www.chartmill.com/stock/quote/BTAI/technical-analysis?key=4e003286-fe0d-4e66-b617-dc7f797b23a3&utm_source=stocktwits&utm_medium=TA&utm_content=BTAI&utm_campaign=social_tracking

User Image ChartMill Posted - 1 day ago

In the last month $BTAI has a been trading in the 20.66 - 32.96 range, which is quite wide. https://www.chartmill.com/stock/quote/BTAI/technical-analysis?key=4e003286-fe0d-4e66-b617-dc7f797b23a3&utm_source=stocktwits&utm_medium=TA&utm_content=BTAI&utm_campaign=social_tracking

User Image ssegduj Posted - 2 days ago

$BTAI Going up up up!!! Buy and hold!!!

User Image Automotive Posted - 2 days ago

$BTAI More information: "First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.open_in_new" Rahul Aggarwal; Jingsong Zhang; Xinhua Zhu; Paul Monk; Robert Jones; Mark Linch; Dan Costin; Johann De Bono; Lawrence Karsh; Daniel Petrylak; Pascal Borderies; Rashmi Deshpande; Amir Hafeez; Vincent O'Neill; Scott Tagawa Affiliations Abstract #176; Pres time: February 16, 2023; 17:10:00 - 17:15:00; "Clinical Trial Registry Number: NCT03910660"

User Image Automotive Posted - 2 days ago

$BTAI Abstracts will be released February 13 at 5pm ET and late breaking abstracts will be released on the day of presentation at 7am PT. Poster Title: "First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results"

User Image Robru Posted - 2 days ago

$BTAI Currently BTAI's presentation of full Phase 2 BXCL701 data is a BPIQ Suspected big Mover. https://www.bpiq.com/post/asco-gu-2023-coming-soon?mo=feb23

User Image Robru Posted - 2 days ago

$BTAI Cambridge Dictionary: "Something that is promising shows signs that it is going to be successful or enjoyable:" Full data will be presented at the 2023 ASCO Genitourinary Cancers Symposium in February. Next catalyst. Sounds good to me. https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-promising-top-line-results-phase

User Image Maineusa1 Posted - 2 days ago

$BTAI no 33 today , oh well maybe next week…

User Image Quantumup Posted - 2 days ago

Impact of Psychotropic Schizophrenia Treatments on Agitation Benzodiazepines May Increase Risk for Psychiatric Readmission @kror74 $BTAI #Igalmi #BXCL501 #sublingualdexmedetomidine #dexmedetomidinesublingualfilm @BioXcel_Tx $krtx $axsm $xbi $nbi https://www.docwirenews.com/docwire-pick/impact-of-psychotropic-schizophrenia-treatments-on-agitation/

User Image Maineusa1 Posted - 2 days ago

$BTAI I think by end of day we will break 33.

User Image kror74 Posted - 3 days ago

$BTAI Let see if we close today above $33. I think so!

User Image Reneejordan001 Posted - 3 days ago

$BTAI SHORTIES Are playing with fire 🔥 😳 😍 👌

User Image ssegduj Posted - 3 days ago

$BTAI Buy all you can and hold!!!

User Image BrahmaBear Posted - 3 days ago

$BTAI today I sat with two reps. The provided the below sample without active ingredients so I placed it on my tongue. It rapidly melted and fells like a listerine strip. There was one seasoned rep and another that was hired within the last month. Important things: 1) we should hear soon about at home administration and it seemed like they will get the indication. Of course they didn’t overtly say. 2) we should get results for dementia indication 2024. 3) they are in with GPOs. The problem is the price in the hospital setting. Once they get the community indication, it will open it up. Then, they get the indication for dementia agitation and it will continue to expand.

User Image BrahmaBear Posted - 3 days ago

$BTAI this is what it looks like.

User Image Irish_lass Posted - 3 days ago

$BTAI I’ll take a close at $32 please.

User Image kror74 Posted - 3 days ago

$BTAI $XBI Above $33 today or Tomorrow

User Image notyouraveragestock Posted - 3 days ago

$BTAI when's the next catalyst?

User Image molson357 Posted - 3 days ago

$BTAI $60 by May 1?

User Image MaverikIT Posted - 3 days ago

@net0trader @Magnificient @Im_not_Mr_Lebowski $BTAI +1.62 - been good

User Image Chi_Moon Posted - 3 days ago

$BTAI Think we might have a pullback once we touch $1B

User Image Maineusa1 Posted - 4 days ago

$BTAI 40 plus by March imo 👍

User Image Maineusa1 Posted - 4 days ago

$BTAI 100 percent !!!

User Image Maineusa1 Posted - 4 days ago

$BTAI re test 26/27 absolutely not !!

User Image kror74 Posted - 4 days ago

$BTAI She (Corina Jetkins) will have to rise again her PT soon!

User Image kror74 Posted - 4 days ago

$BTAI Corina Jetkins!!!!!!! Finally has rise her PT to 26$👏👏👏

User Image mrgermanicus Posted - 4 days ago

$BTAI Corinne Jenkins 🤡

User Image Maineusa1 Posted - 4 days ago

$BTAI $MRK $XBI wouldn’t be surprised if the same happened to Btai…

Analyst Ratings
Goldman Sachs Neutral Dec 1, 22
Mizuho Buy Nov 16, 22
Guggenheim Buy Nov 11, 22
Canaccord Genuity Buy Nov 11, 22
Mizuho Buy Nov 11, 22
HC Wainwright & Co. Buy Aug 24, 22
Mizuho Buy Jul 7, 22
HC Wainwright & Co. Buy May 23, 22
HC Wainwright & Co. Buy Apr 14, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 20 Sell 30.00 50,000 1,500,000 8,397 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Sell 30 29,713 891,390 01/24/23
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Jan 20 Option 0.41 29,713 12,182 29,713 01/24/23
Nandabalan Krishnan Director Director Jan 04 Sell 22.26 60,000 1,335,600 01/06/23
Nandabalan Krishnan Director Director Jan 04 Option 0.41 60,000 24,600 25,889 01/06/23
Mehta Vimal CEO and President CEO and President Dec 15 Option 0.41 60,000 24,600 39,957 12/19/22
Mehta Vimal CEO and President CEO and President Dec 15 Sell 19.8 60,000 1,188,000 9,957 12/19/22
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Option 5.71 25,000 142,750 25,000 02/19/21
O'Neill Vincent Chief Medical Office.. Chief Medical Officer Feb 19 Sell 55.51 25,000 1,387,750 02/19/21
Yocca Frank Chief Scientific Off.. Chief Scientific Officer Jan 27 Option 0.41 15,000 6,150 103,397 01/27/21